DDReg pharma

DELIVER BETTER DATA TO ENSURE FASTER APPROVAL
DDReg Pharma

Blogs

Risk Management Plan

Components of a risk management plan in pharmacovigilance

Overview A drug is authorized by an agency only when it demonstrates a positive risk management-benefit balance or safety profile for the target population. It is a key component of Pharmacovigilance (PV) to safeguard public health. However, information on drug safety gathered from monitoring clinical trials is limited and, at times, not relevant to the larger population […]

Components of a risk management plan in pharmacovigilance Read More »

Drug Safety

Social & Digital Media Sources in Drug Safety

A crucial part of pharmacovigilance (PV) and post-market drug safety surveillance are unsolicited adverse event (AE) reports from various stakeholders including patients, pharmaceutical organizations, and healthcare professionals. These are spontaneous reports and serve as important sources of safety information for a product. Regulatory agencies rely on spontaneous reports for post-market safety surveillance from which they

Social & Digital Media Sources in Drug Safety Read More »

Role of Signal Management in Pharmacovigilance

Role and Importance Signal Management in Pharmacovigilance

A signal is information that arises from single or multiple source/s that may suggest a potential causal association between a drug and event given that the causal relationship between drug & event were previously unknown or inadequately documented. These signals are used for risk-benefit evaluation of a product and emerging safety issues that would cause

Role and Importance Signal Management in Pharmacovigilance Read More »

Inspections

Preparedness for inspections: Are you prepared for the upcoming pharmacovigilance inspection?

Regulatory authorities around the world conduct pharmacovigilance (PV) inspections to verify that marketing authorization holders (MAHs) and allied organizations maintain compliance with PV requirements, obligations, and relevant standards. This applies to products as well as processes. National competent authorities appoint inspectors to conduct these inspections which can be announced or unannounced. If the former, then

Preparedness for inspections: Are you prepared for the upcoming pharmacovigilance inspection? Read More »

Role of Artificial Intelligence in Medico-Regulatory Writing

Enhancing Medico-Regulatory Writing with Artificial Intelligence

Medico-regulatory writing is an important part of regulatory affairs in the Pharmaceutical and Life Sciences industry. Regulatory standards are becoming more stringent in terms of data requirements as a result of ever-changing regulations. So, it is crucial to incorporate the most updated and precise medical information into regulatory applications for pharmaceutical product approval and to

Enhancing Medico-Regulatory Writing with Artificial Intelligence Read More »

Pharmacovigilance and Drug Safety

Automation in Pharmacovigilance and Drug Safety

The integration of artificial intelligence (AI) and machine learning (ML) technology into the pharmaceutical and life sciences industry is demonstrating significant benefits on several fronts. Whether it is incorporation of real-world data into clinical investigations or automation of operations to streamline key processes, technology is driving the industry forward. Pharmacovigilance is part of the industry

Automation in Pharmacovigilance and Drug Safety Read More »

Analytical Assessment Techniques

An overview on the analytical assessment techniques for biosimilar development

Successful biosimilar approval is determined by how well biosimilarity can be demonstrated between the proposed product and its innovator product. An analytical biosimilarity study provides the technical data that would confirm the similarity of critical quality attributes (CQAs) of the proposed product to its innovator in terms of safety, efficacy, and potency. This constitutes comprehensive

An overview on the analytical assessment techniques for biosimilar development Read More »

biosimilar development challenges in immunogenicity assessments

Challenges in immunogenicity assessments for biosimilar development

The biosimilar market is rapidly growing across the globe as patents and exclusivities for biologic products approach their expiration dates. Indeed, biosimilars offer more access due to their affordability which is a key driving factor for market development, particularly in emerging markets with growing economies. However, biosimilar development is prone to many challenges, through all

Challenges in immunogenicity assessments for biosimilar development Read More »